NEW YORK, January 1, 2026, 07:57 ET — Market closed.
- Arcutis shares last closed up 3.4% at $29.04 in the year’s final session.
- A late Form 144 filing showed Arcutis’ chief medical officer plans to sell 1,697 shares. StreetInsider.com+1
- U.S. stock markets are closed Thursday for New Year’s Day and reopen Friday. Intercontinental Exchange
Arcutis Biotherapeutics shares are in focus after a regulatory filing showed an executive planned to sell a small block of stock, with U.S. markets closed on Thursday for New Year’s Day. The dermatology drugmaker last closed up 3.4% at $29.04 on Dec. 31. Intercontinental Exchange
The disclosure matters because investors often track insider selling after sharp moves in biotech stocks, where news flow can shift sentiment quickly. With trading paused for the holiday, the filing gives investors one more data point to weigh before the market reopens on Jan. 2. StreetInsider.com+1
A Form 144 is a notice insiders file before selling “restricted” shares, which are typically shares received through compensation that face resale limits. A filing showed Chief Medical Officer Patrick Burnett plans to sell 1,697 shares through Merrill Lynch, with an aggregate market value listed at about $49,561 and a notice date of Dec. 31. StreetInsider.com+1
The same filing said the shares to be sold were acquired on Dec. 30 through restricted stock vesting, and it listed prior sales over the past three months totaling 35,218 shares. Form 144 filings are notices of intent and do not confirm a sale has occurred. StreetInsider.com
Arcutis traded between $28.08 and $29.67 in the year’s final regular session, according to pricing data. The stock’s move contrasted with a broader market pullback into the close.
In biotech, the SPDR S&P Biotech ETF edged up 0.2% on the last session, while the iShares Nasdaq Biotechnology ETF was little changed. The S&P 500 tracking SPDR ETF fell 0.7%.
Arcutis is a commercial-stage dermatology company whose lead product, Zoryve (roflumilast), is used to treat inflammatory skin diseases. The company has focused on building out Zoryve across multiple indications as its main revenue driver. Reuters+1
At an investor day tied to its third-quarter results in October, Arcutis provided initial 2026 net product sales guidance of $455 million to $470 million and framed the next phase as scaling the franchise. “This success provides a tremendous foundation for sustained, long-term growth,” CEO Frank Watanabe said at the time. Arcutis Biotherapeutics
For investors, the near-term watch list is straightforward: whether prescription growth and pricing dynamics support that 2026 sales outlook, and whether insider selling remains routine or accelerates. Small, pre-announced sales tied to vesting are common, but repeated filings can still weigh on sentiment in momentum names. StreetInsider.com+1
Before the next session on Friday, traders will watch whether Arcutis holds above Wednesday’s $28.08 low and pushes back toward the $30 area after closing at $29.04. Holiday-thinned liquidity can amplify early moves when markets reopen. Intercontinental Exchange
The next major scheduled catalyst is the company’s quarterly report; Zacks expects Arcutis’ next earnings release on Feb. 24, 2026. Any update to the 2026 sales outlook, along with commentary on Zoryve demand, will likely set the tone into early 2026. Zacks+1
